Ovarian Cancer

Trabectedin did not improve median OS and demonstrated a worse safety profile compared to physician’s choice chemotherapy.

The addition of HIPEC to interval cytoreductive surgery for stage III epithelial ovarian cancer significantly improves recurrence-free and overall survival without an increase in severe side effects.

Neoadjuvant chemotherapy and primary debulking surgery showed similar efficacy in terms of progression-free and overall survival. However, neoadjuvant chemotherapy resulted in significantly lower rates of post-operative complications, suggesting a different toxicity profile

The duration of PFS was not significantly increased with either IP regimen when combined with bevacizumab, and was better tolerated than IP cisplatin.

Weekly dose-dense chemotherapy does not significantly improve progression-free survival compared to standard 3-weekly chemotherapy in a predominantly European population.

Niraparib significantly extends progression-free survival among patients with newly diagnosed advanced ovarian cancer post-response to platinum-based chemotherapy, regardless of homologous-recombination deficiency status.

The addition of maintenance olaparib with bevacizumab significantly improves progression-free survival, especially in patients with HRD-positive tumors, including those without a BRCA mutation.

Weekly chemotherapy vs. q3 weekly chemotherapy in advanced ovarian cancer

Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer.

Mirvetuximab Soravtansine (MIRV) in platinum resistant ovarian cancer